Yoshihiro Noguchi, Hiroki Asano, Rikuto Masuda, Yuta Teshigawara, Makiko Go, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura
INTRODUCTION: ALK has been to be involved in the uptake and regulation of D2R, a G protein-coupled receptor expressed in various brain regions. Therefore, it is crucial to understand the relationship between ALK inhibitors and seizures is an important issue. This study investigated the relationship between ALK inhibitors and seizures. METHODS: This study investigated the relationship between ALK inhibitors and seizures through a disproportionality analysis using the FAERS...
May 20, 2024: Oncology
Markus Angerer, Bendix Hansen, Christian Wülfing, Klaus-Peter Dieckmann
Introduction Paraneoplastic hyperthyroidism (PH) has been reported in patients with testicular germ cell tumors (GCTs), sporadically. This disorder is caused by extremely elevated serum levels of beta-human chorionic gonadotropin (bHCG). To date, little is known about the prevalence of PH, and its clinical features are poorly understood. The aim of the present study was to analyze the relative frequency and clinical features of PH in GCTs and evaluate their effects on therapeutic outcomes. Methods A cohort of 438 patients treated for testicular GCT from to 2017-2023 was retrospectively analyzed for histology, age, clinical stage, and presence of PH...
May 6, 2024: Oncology
Elrazi A Ali, Neel Patel, Mazin Khalid, Rasha Kaddoura, Madhumathi Kalavar, Jacob Shani, Mohamed Yassin
Background and Objective Chronic myeloid leukemia (CML) is a hematological malignancy with an excellent prognostic outcome. After advancements in CML treatment and the introduction of different tyrosine kinase inhibitors (TKI), the life expectancy of CML patients has become equivalent to that of the general population. As a result, coronary artery disease is anticipated to be the leading cause of death among CML patients. Moreover, TKI use is associated with a risk of endothelial dysfunction, thrombosis, and cardiovascular events, including myocardial infarction...
May 3, 2024: Oncology
Carolina Jaliffa, Uwe Rogel, Indrani Sen, Gad Singer
INTRODUCTION: Genomic characterization of serous ovarian carcinoma (SOC), which includes low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC), remains necessary to improve efficacy of platinum-based chemotherapy. The aim was to investigate the genomic variations in these SOC groups, also in relation to chemoresponse. METHODS: 45 samples SOC were retrospectively analyzed by Next Generation Sequencing (NGS) on DNA/RNA extracts from formalin-fixed, paraffin-embedded (FFPE) tumor samples obtained at diagnosis...
May 2, 2024: Oncology
(no author information available yet)
No abstract text is available yet for this article.
March 28, 2024: Oncology
Chih-Yang Hsiao, Chang-Yi Lu, Hung-Ju Su, Kai-Wen Huang
INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Lack of biomarkers for follow-up after treatment is a clinical challenge. DNA methylation has been proposed to be a potential biomarker in HCC. However, there is still lacking of evidence of its clinical use. This study aims to evaluate the value of using plasma Adenomatous Polyposis Coli promoter methylation level (APC-MET) as a potential biomarker in HCC treatment. METHOD: A total of 96 patients with HCC at BCLC stage B underwent local tumor ablation treatment were prospectively included in this study...
March 25, 2024: Oncology
Chih-Yang Hsiao, Yayun Ren, Elaine Chng, Dean Tai, Kai-Wen Huang
BACKGROUND: There remains a lack of studies addressing the stromal background and fibrosis features and its prognostic value in liver cancer. qFibrosis can identify, quantify and visualize the fibrosis features from biopsy samples. In this study, we aim to demonstrate the prognostic value of histological features by using qFibrosis analysis in liver cancer patients. METHODS: Liver specimen from 201 patients with hepatocellular carcinoma underwent curative resection were imaged and assessed using qFibrosis system, and generated a total of 33 and 156 collagen parameters from tumor part and non-tumor liver tissue, respectively...
March 25, 2024: Oncology
Tiffany Ting-Fong Liu, Jason Chia-Hsien Cheng, Yu-Hsuan Chen, Feng-Ming Hsu, Keng-Hsueh Lan, Chao-Yuan Huang, Chun-Wei Wang, Sung-Hsin Kuo
INTRODUCTION: The study explored the failure pattern and clinical outcomes in patients with ependymoma undergoing radiotherapy. METHODS: Between January 2004 and June 2022, we included 32 patients with ependymoma who underwent radiotherapy as part of the multimodality treatment at our institution. Of these, 27 (84.4%) underwent adjuvant radiotherapy, four received radiotherapy after local recurrence, and one received definitive CyberKnife radiotherapy (21 Gy in three fractions)...
March 12, 2024: Oncology
Takafumi Fukushima, Kohei Kobatake, Kento Miura, Kenshiro Takemoto, Ryoken Yamanaka, Ryo Tasaka, Yuki Kohada, Shunsuke Miyamoto, Yohei Sekino, Hiroyuki Kitano, Keisuke Goto, Kenichiro Ikeda, Akihiro Goriki, Keisuke Hieda, Osamu Kaminuma, Nobuyuki Hinata
INTRODUCTION: Nuclear envelope spectrin repeat protein (Nesprin) 1 encoded by SYNE1, crucially regulates the morphology and functions of the cell. Mutations in the SYNE1 gene are associated with various diseases; however, their significance in renal cell carcinoma (RCC) remains unknown. In this study, we have investigated the association of SYNE1/Nesprin1 with the progression and prognosis of clear cell RCC (ccRCC). METHODS: In silico analyses of publicly available datasets of patients with RCC were performed...
March 5, 2024: Oncology
Matea Pavic, Qiyu Li, Stephanie Juritz, Arunas Gircys, Anita Wolfer, Ulrich-Peter Rohr
INTRODUCTION: Additional considerations are required for the benefit-risk assessment of new drugs or indications in the setting of (neo)adjuvant cancer treatment as compared to the metastatic/advanced setting, possibly leading to different decision patterns for the (neo)adjuvant versus the metastatic and advanced setting within a health authority but also among different health authorities. METHODS: We analyzed regulatory decisions at the Swiss Agency for Therapeutic Products Swissmedic (SMC) for all oncology indications (mostly metastatic indications) and indications in the (neo)adjuvant setting and compared these to decisions taken by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA)...
March 5, 2024: Oncology
Nehakumari Maurya, Chandrakala Shanmukhaiah, Somprakash Dhangar, Manisha Madkaikar, Babu Rao Vundinti
INTRODUCTION: Myelodysplastic syndrome (MDS) is a heterogeneous disease characterized by cytopenia, marrow dysplasia and has a propensity to develop into acute myeloid leukemia (AML). The disease progression is majorly affected by genetic defects. However, about 40% - 50% of patients with MDS present with a normal karyotype and develop different courses of disease. Hence there remains a room to advance the biological understanding and to find molecular prognostic markers for cytogenetically normal (CN) MDS...
March 5, 2024: Oncology
Phan Nhan Hien, Ho Jong Chun, Jung Suk Oh, Su Ho Kim, Byung Gil Choi
INTRODUCTION: The effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) has been well established. The differential impacts of drug-eluting bead TACE (DEB-TACE) as opposed to conventional TACE (cTACE) on vascular changes, such as arterial-portal venous shunts (APS), have been recognized. However, their subsequent effects on treatment outcomes have not been fully explored. This study aims to identify risk factors associated with the occurrence of APS in HCC patients treated with DEB-TACE and to evaluate its impact on patient survival...
February 26, 2024: Oncology
Luděk Záveský, Eva Jandáková, Vít Weinberger, Luboš Minář, Milada Kohoutová, Ondřej Slanař
Introduction Breast cancer is the most common cancer and the leading cause of cancer death in women. Recent research indicates that human endogenous retroviruses (HERVs) may be linked to carcinogenesis, but the data remain controversial. Methods HERVs´ expression was evaluated to show the differences between breast cancer and control samples, and their associations with clinicopathological parameters. Gene expression of 12 HERVs, i.e. ERVE-4, ERVW-1, ERVFRD-1, ERVV-1, ERV3-1, ERVH48-1, ERVMER34-1, ERVK7, ERVK13-1, ERVK11-1, ERVK3-1 and HCP5 was analyzed by qPCR and/or TCGA datasets for breast cancer...
February 26, 2024: Oncology
Hidenari Nagai, Takanori Mukozu, Teppei Matsui, Kunihide Mohri, Hideki Nagumo, Naoyuki Yoshimine, Kojiro Kobayashi, Yu Ogino, Yasuko Daido, Noritaka Wakui, Koichi Momiyama, Takahisa Matsuda, Yoshinori Igarashi, Koji Higai
INTRODUCTION: Atezolizumab plus bevacizumab (AteBev) combination treatment is widely used as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC). We aimed to clarify therapeutic issues regarding serum cytokines and the immune reaction in patients with uHCC treated with AteBev. METHODS: We analyzed preserved serum from a previous prospective study on adult Japanese patients with chronic liver disease and uHCC who received AteBev treatment at our hospital...
February 23, 2024: Oncology
Koji Numata, Manabu Shiozawa, Yukari Ono, Kenta Iguchi, Mamoru Uchiyama, Masahiro Asari, Yasushi Rino, Aya Saito
[Introduction] Anti-p53 antibody (p53Ab) is useful for monitoring colorectal cancer (CRC) recurrence. We retrospectively analyzed the clinical impact of p53Ab ratio (p53R) before and after surgery to predict recurrence in patients with CRC. [Methods] In total, 1,223 patients with stage I-III CRC who underwent curative surgery between January 2005 and December 2019 were enrolled in this retrospective study. In patients with elevated p53Ab levels, p53R was calculated by measuring p53Ab levels within one month preoperatively and three months postoperatively...
February 21, 2024: Oncology
Mirjana Nedović Vuković, Marina Jakšić, Brigita Smolović, Miloš Lukić, Zoran Bukumirić
Background Gastric cancer (GC) remains a significant global public health problem, despite the decreasing trends in GC mortality rates in the last five decades. Our study aimed to examine the pattern of GC mortality in Montenegro between 1990 and 2018 and to contribute to the future designing a national long-term strategy for the control and prevention of GC. Methods Gastric cancer mortality data in Montenegro from 1990 to 2018 were collected. Mortality rates were age-standardized to the World Standard Population for estimating both the overall and gender-specific trends...
February 19, 2024: Oncology
Olcun Umit Unal, Seval Akay, Gurkan Gul, Murat Keser, Birsen Gizem Ozamrak, Dudu Solakoglu Kahraman, Mihriban Erdogan
INTRODUCTION: Information regarding HER2-low tumors in metastatic gastric cancer is sparse. Our aim here was to determine the frequency of low HER2 expression in metastatic gastric cancer and to compare the clinicopathological characteristics, survival, and treatment response of HER2-low patients with HER2-zero patients. METHODS: All the data were collected retrospectively from computerized system of the hospital. We categorized the patients according to clinicopathological features, treatment responses, and survival in terms of HER2-low tumors and HER2-zero tumors...
February 14, 2024: Oncology
Jing Zhang, Guanya Guo, Tao Li, Changcun Guo, Ying Han, Xinmin Zhou
Introduction Recurrence after microwave ablation (MWA) has not been extensively studied. We aimed to investigate the patterns, treatments, and survival of patients with hepatocellular carcinoma (HCC) who experienced early and late recurrence after MWA. Methods This retrospective study included patients with HCC recurrence after MWA as the initial treatment from January 2008 to December 2021. Recurrence patterns, treatments, and outcomes between patients with early and late HCC recurrence were compared. Prognostic factors of post-recurrence survival (PRS) were identified by multivariable Cox regression analyses...
February 6, 2024: Oncology
Ahmad A Adel, Aimilia Exarchakou, Nurhan Elshafey, Hafedh Ghazouani, Awni Alshurafa, Mohamed A Yassin
BACKGROUND: Lymphoma, encompassing common non-Hodgkin lymphoma (NHL) and less common Hodgkin lymphoma (HL), represents significant hematological malignancies. Advancements in treatment modalities have reshaped survival rates, particularly in NHL. This complexity results in varying outcomes, some requiring extended observation periods and multiple chemotherapy treatments. OBJECTIVE: The primary objective is to explore and compare the overall survival (OS) of HL and NHL at 1, 3, and 5-year follow-ups among adult lymphoma patients in Qatar during January 2013 - December 2017...
February 6, 2024: Oncology
Taro Hirabayashi, Kei Sonehara, Ryota Ozawa, Tsutomu Hachiya, Shuhei Nozawa, Toshihiko Agatsuma, Hiroshi Yamamoto, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
INTRODUCTION: Combination therapy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies and platinum-based chemotherapy has been widely used as a first-line treatment for patients with unresectable advanced non-small cell lung cancer (NSCLC) in clinical settings; however, prognostic biomarkers associated with survival outcomes have not been sufficiently investigated. METHODS: We enrolled 147 previously untreated patients with advanced NSCLC who were treated with a combination therapy of anti-PD-1/-PD-L1 antibodies and platinum-based chemotherapy at eight institutions in Nagano Prefecture between December 2018 and April 2023...
February 6, 2024: Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.